Dysregulation of the mTOR pathway in p53-deficient mice

References

• Vogelstein B, Lane DP, Levine AJ. Surfing the p53 network. Nature 2000; 408:307 - 10; http://dx.doi.org/10.1038/35042675; PMID: 11099028
   PubMed Web of Science ®Google Scholar
• Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ 2007; 14:3 - 9; http://dx.doi.org/10.1038/sj.cdd.4402058; PMID: 17068503
   PubMed Web of Science ®Google Scholar
• Gudkov AV, Komarova EA. Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 2007; 16:Spec No 1 R67 - 72; http://dx.doi.org/10.1093/hmg/ddm052; PMID: 17613549
   PubMed Web of Science ®Google Scholar
• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749 - 58; http://dx.doi.org/10.1038/nrc2723; PMID: 19776744
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413 - 31; http://dx.doi.org/10.1016/j.cell.2009.04.037; PMID: 19410540
   PubMed Web of Science ®Google Scholar
• Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149:1269 - 83; http://dx.doi.org/10.1016/j.cell.2012.04.026; PMID: 22682249
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?. Aging (Albany NY) 2012; 4:450 - 5; PMID: 22869016
   PubMedGoogle Scholar
• Zhu Y, Prives C. p53 and Metabolism: The GAMT Connection. Mol Cell 2009; 36:351 - 2; http://dx.doi.org/10.1016/j.molcel.2009.10.026; PMID: 19917243
   PubMed Web of Science ®Google Scholar
• Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20:427 - 34; http://dx.doi.org/10.1016/j.tcb.2010.03.004; PMID: 20399660
   PubMed Web of Science ®Google Scholar
• Altilia S, Santoro A, Malagoli D, Lanzarini C, Ballesteros Álvarez JA, Galazzo G, Porter DC, Crocco P, Rose G, Passarino G, et al. TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells. Aging (Albany NY) 2012; 4:28 - 39; PMID: 22289634
   PubMedGoogle Scholar
• Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P, Mahdi AA. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2011; 2:948 - 57; PMID: 22248668
   PubMed Web of Science ®Google Scholar
• Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov AV. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A 2013; 110:E89 - 98; http://dx.doi.org/10.1073/pnas.1216922110; PMID: 23236145
   PubMed Web of Science ®Google Scholar
• Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 2005; 102:17448 - 53; http://dx.doi.org/10.1073/pnas.0508888102; PMID: 16287968
   PubMed Web of Science ®Google Scholar
• Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 2009; 8:4168 - 75; http://dx.doi.org/10.4161/cc.8.24.10800; PMID: 20054236
   PubMed Web of Science ®Google Scholar
• Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, Hensold JO. p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene 2002; 21:5325 - 34; http://dx.doi.org/10.1038/sj.onc.1205662; PMID: 12149653
   PubMed Web of Science ®Google Scholar
• Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. Regulation of PTEN transcription by p53. Mol Cell 2001; 8:317 - 25; http://dx.doi.org/10.1016/S1097-2765(01)00323-9; PMID: 11545734
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005; 102:8204 - 9; http://dx.doi.org/10.1073/pnas.0502857102; PMID: 15928081
   PubMed Web of Science ®Google Scholar
• Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267 - 75; http://dx.doi.org/10.1101/gad.1363206; PMID: 16452501
   PubMed Web of Science ®Google Scholar
• Levine AJ, Harris CR, Puzio-Kuter AM. The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway. Oncotarget 2012; 3:1301 - 7; PMID: 23211569
   PubMed Web of Science ®Google Scholar
• Loayza-Puch F, Drost J, Rooijers K, Lopes R, Elkon R, Agami R. p53 induces transcriptional and translational programs to suppress cell proliferation and growth. Genome Biol 2013; 14:R32; http://dx.doi.org/10.1186/gb-2013-14-4-r32; PMID: 23594524
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A 2010; 107:9660 - 4; http://dx.doi.org/10.1073/pnas.1002298107; PMID: 20457898
   PubMed Web of Science ®Google Scholar
• Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010; 2:344 - 52; PMID: 20606252
   PubMedGoogle Scholar
• Tucci P. Caloric restriction: is mammalian life extension linked to p53?. Aging (Albany NY) 2012; 4:525 - 34; PMID: 22983298
   PubMedGoogle Scholar
• de Keizer PL, Laberge RM, Campisi J. p53: Pro-aging or pro-longevity?. Aging (Albany NY) 2010; 2:377 - 9; PMID: 20657035
   PubMedGoogle Scholar
• Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6:2853 - 68; http://dx.doi.org/10.1371/journal.pbio.0060301; PMID: 19053174
   PubMed Web of Science ®Google Scholar
• Lee JH, Bodmer R, Bier E, Karin M. Sestrins at the crossroad between stress and aging. Aging (Albany NY) 2010; 2:369 - 74; PMID: 20606249
   PubMedGoogle Scholar
• Horikawa I, Fujita K, Harris CC. p53 governs telomere regulation feedback too, via TRF2. Aging (Albany NY) 2011; 3:26 - 32; PMID: 21266744
   PubMedGoogle Scholar
• Dulic V. Be quiet and you’ll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence?. Aging (Albany NY) 2011; 3:3 - 4; PMID: 21248373
   PubMedGoogle Scholar
• Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2:535 - 7; PMID: 20876940
   PubMedGoogle Scholar
• McGee MD, Day N, Graham J, Melov S. cep-1/p53-dependent dysplastic pathology of the aging C. elegans gonad. Aging (Albany NY) 2012; 4:256 - 69; PMID: 22562940
   PubMedGoogle Scholar
• Chao SK, Horwitz SB, McDaid HM. Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence. Oncotarget 2011; 2:89 - 98; PMID: 21399233
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2010; 2:924 - 35; PMID: 21212465
   PubMedGoogle Scholar
• Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A 2012; 109:13314 - 8; http://dx.doi.org/10.1073/pnas.1205690109; PMID: 22847439
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012; 4:159 - 65; PMID: 22394614
   PubMedGoogle Scholar
• Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 2012; 11:2391 - 401; http://dx.doi.org/10.4161/cc.20683; PMID: 22627671
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11:4642 - 9; http://dx.doi.org/10.4161/cc.22937; PMID: 23187803
   PubMed Web of Science ®Google Scholar
• Krtolica A, Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol 2002; 34:1401 - 14; http://dx.doi.org/10.1016/S1357-2725(02)00053-5; PMID: 12200035
   PubMed Web of Science ®Google Scholar
• Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci 2005; 118:485 - 96; http://dx.doi.org/10.1242/jcs.01635; PMID: 15657080
   PubMed Web of Science ®Google Scholar
• Martens JW, Sieuwerts AM, Bolt-deVries J, Bosma PT, Swiggers SJ, Klijn JG, Foekens JA. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb Haemost 2003; 89:393 - 404; PMID: 12574821
   PubMed Web of Science ®Google Scholar
• Mikheev AM, Stoll EA, Ramakrishna R, Mikheeva SA, Horner PJ, Rostomily RC. Geropotency: increased malignant potential of aging neural progenitors. Aging (Albany NY) 2012; 4:854 - 5; PMID: 23257545
   PubMedGoogle Scholar
• Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, Goldberg AF, Pestell RG, Howell A, Sneddon S, et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 2012; 11:2285 - 302; http://dx.doi.org/10.4161/cc.20718; PMID: 22684298
   PubMed Web of Science ®Google Scholar
• Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 2012; 181:278 - 93; http://dx.doi.org/10.1016/j.ajpath.2012.03.017; PMID: 22698676
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Warfel NA, El-Deiry WS. CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis. Cell Cycle 2012; 11:2592 - 3; http://dx.doi.org/10.4161/cc.21240; PMID: 22751431
   PubMed Web of Science ®Google Scholar
• Lewis DA, Travers JB, Machado C, Somani AK, Spandau DF. Reversing the aging stromal phenotype prevents carcinoma initiation. Aging (Albany NY) 2011; 3:407 - 16; PMID: 21515933
   PubMedGoogle Scholar
• Greaves M. Leukemogenesis and ageing: 'fit for transformation'?. Aging (Albany, NY Online) 2011; 3:79 - 80
   PubMedGoogle Scholar
• Henry CJ, Marusyk A, DeGregori J. Aging-associated changes in hematopoiesis and leukemogenesis: what’s the connection?. Aging (Albany NY) 2011; 3:643 - 56; PMID: 21765201
   PubMedGoogle Scholar
• Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Viña J, Blasco MA, Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007; 448:375 - 9; http://dx.doi.org/10.1038/nature05949; PMID: 17637672
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520 - 4; http://dx.doi.org/10.4161/cbt.7.10.6663; PMID: 18769112
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 2011; 3:1130 - 41; PMID: 22246147
   PubMedGoogle Scholar
• Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3:148 - 57; PMID: 21386129
   PubMedGoogle Scholar
• Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer?. Cancer Biol Ther 2012; 13:1349 - 54; http://dx.doi.org/10.4161/cbt.22859; PMID: 23151465
   PubMed Web of Science ®Google Scholar
• Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY) 2012; 4:320 - 9; PMID: 22589237
   PubMedGoogle Scholar
• Stipp D. A new path to longevity. Sci Am 2012; 306:32 - 9; http://dx.doi.org/10.1038/scientificamerican0112-32; PMID: 22279832
   PubMed Web of Science ®Google Scholar
• Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, Kockel L. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010; 11:453 - 65; http://dx.doi.org/10.1016/j.cmet.2010.05.001; PMID: 20519118
   PubMed Web of Science ®Google Scholar
• Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493:338 - 45; http://dx.doi.org/10.1038/nature11861; PMID: 23325216
   PubMed Web of Science ®Google Scholar
• Kaeberlein M. Longevity and aging. F1000Prime Rep 2013; 5:5; http://dx.doi.org/10.12703/P5-5; PMID: 23513177
   PubMedGoogle Scholar
• Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010; 11:35 - 46; http://dx.doi.org/10.1016/j.cmet.2009.11.010; PMID: 20074526
   PubMed Web of Science ®Google Scholar
• Flynn JM, O’Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, Zykovich A, Mooney SD, Strong R, Rosen CJ, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 2013; 12:851 - 62; http://dx.doi.org/10.1111/acel.12109; PMID: 23734717
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. How to save Medicare: the anti-aging remedy. Aging (Albany NY) 2012; 4:547 - 52; PMID: 22915707
   PubMedGoogle Scholar
• Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215 - 21; http://dx.doi.org/10.1038/356215a0; PMID: 1552940
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr., Park SH, Thompson T, Ford RJ, Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995; 14:16 - 22; http://dx.doi.org/10.1002/mc.2940140105; PMID: 7546219
   PubMed Web of Science ®Google Scholar
• Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4:1 - 7; http://dx.doi.org/10.1016/S0960-9822(00)00002-6; PMID: 7922305
   PubMed Web of Science ®Google Scholar
• Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) 2012; 4:709 - 14; PMID: 23123616
   PubMedGoogle Scholar
• Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV, Antoch MP. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) 2012; 4:715 - 22; PMID: 23117593
   PubMedGoogle Scholar
• Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging (Albany NY) 2012; 4:660 - 1; PMID: 23128359
   PubMedGoogle Scholar
• Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, et al. p53 is a suppressor of inflammatory response in mice. FASEB J 2005; 19:1030 - 2; PMID: 15811878
   PubMed Web of Science ®Google Scholar
• Gudkov AV, Gurova KV, Komarova EA. Inflammation and p53: A Tale of Two Stresses. Genes Cancer 2011; 2:503 - 16; http://dx.doi.org/10.1177/1947601911409747; PMID: 21779518
   PubMedGoogle Scholar
• Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 1999; 5:335 - 9; http://dx.doi.org/10.1038/6585; PMID: 10086392
   PubMed Web of Science ®Google Scholar
• van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, Vierboom MP, van Eck M, van De Water B, van Berkel TJ, et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res 2001; 88:780 - 6; http://dx.doi.org/10.1161/hh0801.089261; PMID: 11325869
   PubMed Web of Science ®Google Scholar
• Mercer J, Bennett M. The role of p53 in atherosclerosis. Cell Cycle 2006; 5:1907 - 9; http://dx.doi.org/10.4161/cc.5.17.3166; PMID: 16929177
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) 2012; 4:899 - 916; PMID: 23443503
   PubMedGoogle Scholar
• Leontieva OV, Paszkiewicz G, Demidenko ZN, Blagosklonny MV. Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. Cell Death Dis 2013; 4:e472; http://dx.doi.org/10.1038/cddis.2012.202; PMID: 23348586
   PubMed Web of Science ®Google Scholar
• van Heemst D, Beekman M, Mooijaart SP, Heijmans BT, Brandt BW, Zwaan BJ, Slagboom PE, Westendorp RG. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell 2005; 4:79 - 85; http://dx.doi.org/10.1111/j.1474-9728.2005.00148.x; PMID: 15771611
   PubMed Web of Science ®Google Scholar
• Yuan R, Tsaih SW, Petkova SB, Marin de Evsikova C, Xing S, Marion MA, Bogue MA, Mills KD, Peters LL, Bult CJ, et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 2009; 8:277 - 87; http://dx.doi.org/10.1111/j.1474-9726.2009.00478.x; PMID: 19627267
   PubMed Web of Science ®Google Scholar
• Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, Lamberts SW, Monti D, Bucci L, Cevenini E, et al. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians’ offspring. Aging (Albany NY) 2012; 4:580 - 9; PMID: 22983440
   PubMedGoogle Scholar
• Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431:200 - 5; http://dx.doi.org/10.1038/nature02866; PMID: 15306821
   PubMed Web of Science ®Google Scholar
• Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14:1650 - 6; http://dx.doi.org/10.1016/j.cub.2004.08.026; PMID: 15380067
   PubMed Web of Science ®Google Scholar
• Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326:140 - 4; http://dx.doi.org/10.1126/science.1177221; PMID: 19797661
   PubMed Web of Science ®Google Scholar
• Masternak MM, Panici JA, Bonkowski MS, Hughes LF, Bartke A. Insulin sensitivity as a key mediator of growth hormone actions on longevity. J Gerontol A Biol Sci Med Sci 2009; 64:516 - 21; http://dx.doi.org/10.1093/gerona/glp024; PMID: 19304940
   PubMed Web of Science ®Google Scholar
• Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 2008; 105:3438 - 42; http://dx.doi.org/10.1073/pnas.0705467105; PMID: 18316725
   PubMed Web of Science ®Google Scholar
• Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003; 299:1346 - 51; http://dx.doi.org/10.1126/science.1081447; PMID: 12610294
   PubMed Web of Science ®Google Scholar
• Bartke A. Long-lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. Trends Endocrinol Metab 2006; 17:33 - 5; http://dx.doi.org/10.1016/j.tem.2006.01.002; PMID: 16458526
   PubMed Web of Science ®Google Scholar
• Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3:70ra13; http://dx.doi.org/10.1126/scitranslmed.3001845; PMID: 21325617
   PubMed Web of Science ®Google Scholar
• Bartke A. Healthy aging: is smaller better? - a mini-review. Gerontology 2012; 58:337 - 43; http://dx.doi.org/10.1159/000335166; PMID: 22261798
   PubMed Web of Science ®Google Scholar
• Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3:192 - 222; PMID: 21422497
   PubMedGoogle Scholar
• Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget 2012; 3:1566 - 75; PMID: 23248156
   PubMed Web of Science ®Google Scholar
• Hursting SD, Perkins SN, Phang JM. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A 1994; 91:7036 - 40; http://dx.doi.org/10.1073/pnas.91.15.7036; PMID: 8041741
   PubMed Web of Science ®Google Scholar
• Leonova KI, Shneyder J, Antoch MP, Toshkov IA, Novototskaya LR, Komarov PG, Komarova EA, Gudkov AV. A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle 2010; 9:1434 - 43; http://dx.doi.org/10.4161/cc.9.7.11508; PMID: 20404530
   PubMed Web of Science ®Google Scholar